• India has administered more than one crore doses of the Human Papillomavirus (HPV) vaccine to 14-year-old girls under the National HPV Vaccination Campaign in less than nine months of its launch.
• The achievement marks a significant step towards protecting adolescent girls against HPV infections that can cause cervical cancer and reflects the growing reach of preventive healthcare services across the country.
When was the campaign launched?
• The National HPV Vaccination Campaign was launched in February 2026.
• It provides free, safe and voluntary single-dose HPV vaccination, with parental consent, to 14-year-old girls at government health facilities.
• The campaign has achieved nearly 87 per cent cumulative coverage against the identified annual target cohort of approximately 1.2 crore girls.
Six states achieve 100 per cent coverage
• Six states — Gujarat, Uttar Pradesh, Andhra Pradesh, Mizoram, Madhya Pradesh and Bihar — have achieved 100 per cent coverage of their identified target populations under the campaign.
• Among other high-performing states, Assam has recorded 95.63 per cent coverage, followed by Telangana (95.28 per cent), Karnataka (93.16 per cent) and Uttarakhand (90.17 per cent).
• Chhattisgarh (86.21 per cent) and Rajasthan (85.23 per cent) have crossed the 80 per cent coverage mark, while Kerala (77.02 per cent), Tamil Nadu (76.12 per cent), Odisha (74.90 per cent) and the Union Territory of Dadra and Nagar Haveli and Daman and Diu (72.99 per cent) have achieved more than 70 per cent coverage.
• In terms of absolute numbers, Uttar Pradesh leads the country with more than 29.33 lakh 14-year-old girls vaccinated, followed by Bihar with over 13.70 lakh and Gujarat with over 7.75 lakh girls vaccinated.
Key points on HPV:
• Human papillomavirus (HPV) is a small, non-enveloped deoxyribonucleic acid (DNA) virus that infects skin or mucosal cells.
• HPV is a common sexually transmitted infection.
• It can affect the skin, genital area and throat.
• HPV usually goes away on its own without treatment. The immune system usually clears HPV from the body within a year or two with no lasting effects.
• Some HPV infections cause genital warts. Others can cause abnormal cells to develop, which go on to become cancer.
• At least 13 of more than 100 known HPV genotypes can cause cancer of the cervix and are associated with other anogenital cancers and cancers of the head and neck.
• The two most common ‘high-risk’ genotypes (HPV 16 and 18) cause approximately 70 per cent of all cervical cancers.
• Cancers from HPV can be prevented with vaccines.
• Currently, cervical cancer is the only HPV-caused cancer for which screening tests are available.
Key points on cervical cancer:
• Globally, cervical cancer is the fourth most common cancer in women.
• Cervical cancer develops in a woman’s cervix (the entrance to the uterus from the vagina).
• Cervical cancer starts in the cells of the cervix.
• The cervix connects the uterus to the vagina (birth canal).
• Cervical cancer usually develops slowly over time. Before cancer appears in the cervix, the cells of the cervix go through changes known as dysplasia, in which abnormal cells begin to appear in the cervical tissue. Over time, if not destroyed or removed, the abnormal cells may become cancer cells and start to grow and spread more deeply into the cervix and to surrounding areas.
• Almost all cervical cancer cases are linked to infection with high-risk human papillomaviruses (HPV).
• Effective primary (HPV vaccination) and secondary prevention approaches (screening for, and treating precancerous lesions) will prevent most cervical cancer cases.
• When diagnosed, cervical cancer is one of the most successfully treatable forms of cancer, as long as it is detected early and managed effectively.
• With a comprehensive approach to prevent, screen and treat, cervical cancer can be eliminated as a public health problem.